WA
ECYT

WFG Advisors’s Endocyte, Inc. Common Stock ECYT Stock Holding History

WFG Advisors’s Portfolio ECYT Stock Details ECYT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q4 		– Sell
-930
Closed -$3K – 1814
2016
Q3 		$3K Hold
930
– – ﹤0.01% 1374
2016
Q2 		$3K Hold
930
– – ﹤0.01% 1351
2016
Q1 		$3K Hold
930
– – ﹤0.01% 1310
2015
Q4 		$4K Hold
930
– – ﹤0.01% 1284
2015
Q3 		$4K Hold
930
– – ﹤0.01% 1323
2015
Q2 		$5K Hold
930
– – ﹤0.01% 1365
2015
Q1 		$6K Hold
930
– – ﹤0.01% 1343
2014
Q4 		$6K Hold
930
– – ﹤0.01% 1617
2014
Q3 		$6K Buy
+930
New +$6.35K ﹤0.01% 1634

Other funds holding ECYT

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
PA
Pinnacle Associates New York $7.78B AUM 45.07% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
HCMT
Highland Capital Management (Texas) Dallas, Texas $39M AUM
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

WFG Advisors's ECYT Position: Q4 2016 in Review

WFG Advisors sold out of Endocyte, Inc. Common Stock (ECYT) in Q4 2016, closing a stake of 930 shares — an estimated $3K sold.

WFG Advisors first reported a position in ECYT in Q3 2014 and held it in 9 quarters. The position peaked at $6K in Q1 2015. 96 funds tracked by Wall St. Rank hold ECYT as of Q4 2016.

  • WFG Advisors reported no remaining Endocyte, Inc. Common Stock position as of Q4 2016 after selling out during the quarter.
  • WFG Advisors sold 930 Endocyte, Inc. Common Stock shares in Q4 2016, an estimated $3K.
  • WFG Advisors first reported a position in Endocyte, Inc. Common Stock in Q3 2014 and held it in 9 quarters.
  • WFG Advisors's Endocyte, Inc. Common Stock position peaked at $6K in Q1 2015.
  • 96 funds tracked by Wall St. Rank held Endocyte, Inc. Common Stock as of Q4 2016.

Based on WFG Advisors's 13F filing for Q4 2016, filed 1 Mar 2017.